Tinkering outside the kinase ATP box: Allosteric (type IV) and bivalent (type V) inhibitors of protein kinases

Future Medicinal Chemistry

Volumn 3, Issue 1, 2011, Pages 29-43

  Cox, Kurt J ^a   Shomin, Carolyn D ^a   Ghosh, Indraneel ^a  

^a University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DASATINIB; DORAMAPIMOD; IMATINIB; IRS 272; IRS 727; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PD 318088; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; STAUROSPORINE; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING SITE; CHRONIC MYELOID LEUKEMIA; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SUBSTRATE; HIGH THROUGHPUT SCREENING; HUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 78650657590     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.272     Document Type: Review

References (82)

1. Cohen P. The regulation of protein function by multisite phosphorylation - a 25 year update. Trends Biochem. Sci. 25(12), 596-601 (2000).
2. Johnson LN. The regulation of protein phosphorylation. Biochem. Soc. Trans. 37, 627-641 (2009).
3. Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell 138(5), 838-854 (2009).
4. Hartwell LH, Kastan MB. Cell-cycle control and cancer. Science 266(5192), 1821-1828 (1994).
5. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 17(1), 60-65 (2007).
6. Zhang JM, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9(1), 28-39 (2009).
7. Fedorov O, Muller S, Knapp S. The (un) targeted cancer kinome. Nat. Chem. Biol. 6(3), 166-169 (2010).
8. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Disc. 1(4), 309-315 (2002).
9. OBrien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348(11), 994-1004 (2003).
10. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 298(5600), 1912-1934 (2002).
11. Gray NS, Wodicka L, Thunnissen A et al. Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors. Science 281(5376), 533-538 (1998).
12. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291(5507), 1304-1351 (2001).
13. Bain J, Plater L, Elliott M et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315 (2007).
14. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotech. 26(1), 127-132 (2008).
15. Jester BW, Cox KJ, Gaj A, Shomin CD, Porter JR, Ghosh I. A coiled-coil enabled split-luciferase three-hybrid system for profiling inhibitors of protein kinases. J. Am. Chem. Soc. 132(33), 11727-11735 (2010).
16. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem. Biol. 12(6), 621-637 (2005).
17. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca2+ dependent protein-kinase. Biochem. Biophys. Res. Commun. 135(2), 397-402 (1986).
18. Ruegg UT, Burgess GM. Staurosporine, K-252 and UCN-01 - potent but nonspecific inhibitors of protein-kinases. Trends Pharmacol. Sci. 10(6), 218-220 (1989).
19. Bridges AJ. Chemical inhibitors of protein kinases. Chem. Rev. 101(8), 2541-2571 (2001).
20. McInnes C, Fischer PM. Strategies for the design of potent and selective kinase inhibitors. Curr. Pharm. Des. 11(14), 1845-1863 (2005).
21. Li B, Liu Y, Uno T, Gray N. Creating chemical diversity to target protein kinases. Comb. Chem. High Throughput Screen. 7(5), 453-472 (2004).
22. Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today 12(15-16), 622-633 (2007).
23. Lewis JA, Lebois EP, Lindsley CW. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Curr. Opin. Chem. Biol. 12(3), 269-280 (2008).
24. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289(5486), 1938-1942 (2000).
25. Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble MEM. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. 93(2-3), 125-133 (2002).
26. Pargellis C, Tong L, Churchill L et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9(4), 268-272 (2002).
27. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2(7), 358-364 (2006).
28. Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62(15), 4236-4243 (2002).
29. Okram B, Nagle A, Adrian FJ et al. A general strategy for creating inactive-conformation Abl inhibitors. Chem. Biol. 13(7), 779-786 (2006).
30. Kalesh KA, Liu K, Yao SQ. Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry. Org. Biomol. Chem. 7(24), 5129-5136 (2009).
31. Simard JR, Kluter S, Grutter C et al. A new screening assay for allosteric inhibitors of cSrc. Nat. Chem. Biol. 5(6), 394-396 (2009).
32. Simard JR, Grutter C, Pawar V et al. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38 a. J. Am. Chem. Soc. 131(51), 18478-18488 (2009).
33. Ohren JF, Chen HF, Pavlovsky A et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11(12), 1192-1197 (2004).
34. Kodadek T. Rethinking screening. Nat. Chem. Biol. 6(3), 162-165 (2010).
35. Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308(5726), 1318-1321 (2005).
36. Ye GF, Tiwari R, Parang K. Development of Src tyrosine kinase substrate binding site inhibitors. Curr. Opin. Invest. Drugs 9(6), 605-613 (2008).
37. Wu J, Meng F, Ying Y et al. ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinibresistant cells. Leukemia 24(4), 869-872 (2010).
38. Porter JR, Helmers MR, Wang P et al. Profiling small molecule inhibitors against helix-receptor interactions: the Bcl-2 family inhibitor BH3I-1 potently inhibits p53/hDM2. Chem. Commun. 46(42), 8020-8022 (2010).
39. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450(7172), 1001-1009 (2007).
40. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204 (2003).
41. Fabian MA, Biggs WH, Treiber DK et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotech. 23(3), 329-336 (2005).
42. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 109(3), 275-282 (2002).
43. Converso A, Hartingh T, Garbaccio RM et al. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg. Med. Chem. Lett. 19(4), 1240-1244 (2009).
44. Vanderpool D, Johnson TO, Ping C et al. Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry 48(41), 9823-9830 (2009).
45. Barnett SF, Defeo-Jones D, Fu S et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399-408 (2005).
46. Zhao ZJ, William HL, Robinson RG et al. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent AM Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett. 15(4), 905-909 (2005).
47. Hartnett JC, Barnett SF, Bilodeau MT et al. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. Bioorg. Med. Chem. Lett. 18(6), 2194-2197 (2008).
48. Wu WI, Voegtli WC, Sturgis HL, Dizon FP, Vigers GPA, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. Plos One 5(9), 9 (2010).
49. Calleja V, Alcor D, Laguerre M et al. Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. Plos Biol. 5(4), 780-791 (2007).
50. Deacon SW, Beeser A, Fukui JA et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol. 15(4), 322-331 (2008).
51. Lei M, Lu WG, Meng WY et al. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 102(3), 387-397 (2000).
52. Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol. Cancer Ther. 8(9), 2559-2565 (2009).
53. Bobkova EV, Weber MJ, Xu ZW et al. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. J. Biol. Chem. 285(24), 18838-18846 (2010).
54. Biondi RM, Cheung PCF, Casamayor A, Deak M, Currie RA, Alessi DR. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J. 19(5), 979-988 (2000).
55. Adrian FJ, Ding Q, Sim TB et al. Allosteric inhibitors of Bcr-Abl-dependent cell proliferation. Nat. Chem. Biol. 2(2), 95-102 (2006).
56. Hantschel O, Nagar B, Guettler S et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112(6), 845-857 (2003).
57. Zhang JM, Adrian FJ, Jahnke W et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463(7280), 501-506 (2010).
58. Gumireddy K, Reddy MVR, Cosenza SC et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7(3), 275-286 (2005).
59. Kim D, Sun M, He LL et al. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J. Biol. Chem. 285(11), 8383-8394 (2010).
60. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Inter. Ed. 44(27), 4130-4163 (2005).
61. Arkin MR, Whitty A. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr. Opin. Chem. Biol. 13(3), 284-290 (2009).
62. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3(4), 301-317 (2004).
63. Jencks WP. On the attribution and additivity of binding-energies. Proc. Natl. Acad. Sci. USA 78(7), 4046-4050 (1981).
64. Lavogina D, Enkvist E, Uri A. Bisubstrate inhibitors of protein kinases: from principle to practical applications. ChemMedChem 5(1), 23-34 (2010).
65. Parang K, Cole PA. Designing bisubstrate analog inhibitors for protein kinases. Pharmacol. Ther. 93(2-3), 145-157 (2002).
66. Parang K, Till JH, Ablooglu AJ, Kohanski RA, Hubbard SR, Cole PA. Mechanism-based design of a protein kinase inhibitor. Nat. Struct. Biol. 8(1), 37-41 (2001).
67. Obata T, Yaffe MB, Leparc GG et al. Peptide and protein library screening defines optimal substrate motifs for Akt/PKB. J. Biol. Chem. 275(46), 36108-36115 (2000).
68. Ricouart A, Gesquiere JC, Tartar A, Sergheraert C. Design of potent protein-kinase inhibitors using the bisubstrate approach. J. Med. Chem. 34(1), 73-78 (1991).
69. Lavogina D, Lust M, Viil I et al. Structural analysis of arc-type inhibitor (arc-1034) binding to protein kinase a catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. J. Med. Chem. 52(2), 308-321 (2009).
70. van Ameijde J, Poot AJ, van Wandelen LTM et al. Preparation of novel alkylated arginine derivatives suitable for click-cycloaddition chemistry and their incorporation into pseudosubstrate- and bisubstrate-based kinase inhibitors. Org. Biomole. Chem. 8(7), 1629-1639 (2010).
71. Schneider TL, Mathew RS, Rice KP, Tamaki K, Wood JL, Schepartz A. Increasing the kinase specificity of K252a by protein surface recognition. Org. Lett. 7(9), 1695-1698 (2005).
72. Lee JH, Kumar S, Lawrence DS. Stepwise combinatorial evolution of Akt bisubstrate inhibitors. ChemBioChem 9(4), 507-509 (2008).
73. Lee JH, Nandy SK, Lawrence DS. A highly potent and selective PKC a inhibitor generated via combinatorial modification of a peptide scaffold. J. Am. Chem. Soc. 126(11), 3394-3395 (2004).
74. Profit AA, Lee TR, Lawrence DS. Bivalent inhibitors of protein tyrosine kinases. J. Am. Chem. Soc. 121(2), 280-283 (1999).
75. Hah JM, Sharma V, Li HS, Lawrence DS. Acquisition of a group A-selective Src kinase inhibitor via a global targeting strategy. J. Am. Chem. Soc. 128(18), 5996-5997 (2006).
76. Hill ZB, Perera BGK, Maly DJ. A chemical genetic method for generating bivalent inhibitors of protein kinases. J. Am. Chem. Soc. 131(19), 6686-6688 (2009).
77. Meyer SC, Shomin CD, Gaj T, Ghosh I. Tethering small molecules to a phage display library: discovery of a selective bivalent inhibitor of protein kinase A. J. Am. Chem. Soc. 129(45), 13812-13813 (2007).
78. Shomin CD, Meyer SC, Ghosh I. Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling. Bioorg. Med. Chem. 17(17), 6196-6202 (2009).
79. Porter JR, Stains CI, Jester BW, Ghosh I. A general and rapid cell-free approach for the interrogation of protein-protein, protein- DNA, and protein-RNA interactions and their antagonists utilizing split-protein reporters. J. Am. Chem. Soc. 130(20), 6488-6497 (2008).
80. Jester BW, Cox KJ, Gaj A, Shomin CD, Porter JR, Ghosh I. A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases. J. Am. Chem. Soc. 132(33), 11727-11735 (2010).
81. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2), 117-125 (2002).
82. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 15(10), 1109-1118 (2008).